Physician profile
Robert J Karnes
NPI 1679569602
$29,182.73
in general payments reported to CMS, 2019-2025
10 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,726 · 2022: $6,189 · 2023: $4,684 · 2024: $2,668 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,134 · Food and Beverage: $1,102 · Travel and Lodging: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,951.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,134.00 |
| Food and Beverage | $1,102.29 |
| Travel and Lodging | $1,080.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $9,877.18 | 2021-2025 | |
| Nucletron Operations B.V. | $5,337.31 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $4,934.12 | 2023-2024 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $4,701.29 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $2,781.04 | 2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals Lp | $1,117.50 | 2025 | Imfinzi, Lynparza |
| Cook Medical LLC | $248.49 | 2024-2025 | Litho 150 |
| Telix Pharmaceuticals | $75.44 | 2023 | Illuccix |
| Blue Earth Diagnostics | $68.28 | 2024-2025 | Posluma |
| Laborie Medical Technologies Corp. | $42.08 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Karnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.